Date: 2016-09-29
Type of information: Licensing agreement
Compound: HM95573
Company: Genentech, a member of Roche Group (USA - CA - Switzerland) Hanmi Pharmaceutical (Republic of Korea)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: pan-RAF inhibitor. RAF kinases, consisted of three subtypes (A-RAF, B-RAF, C-RAF), are one of the mitogen activated protein kinases (MAP Kinase) that transduce signals in cells, and especially B-RAF and C-RAF are known to be associated with various cancers.
Disease:
Details: * On September 29, 2016, Hanmi Pharmaceutical announced that it has entered into an exclusive development and license agreement with Genentech for the development and commercialization of Hanmi’s pan-RAF inhibitor, HM95573 which is currently in Phase I clinical development. Under the terms of the agreement, Genentech will obtain exclusive worldwide rights, except South Korea, to develop and commercialize HM95573.
Financial terms: Hanmi will receive an initial upfront payment of $80 million and is eligible to receive payments based on achievement of certain predetermined development, regulatory and commercialization milestones totaling up to $830 million. In addition, Hanmi is eligible to receive tiered double digit royalties on sales of certain products resulting from the license agreement. Full financial terms have not been disclosed.
Latest news:
